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ABSTRACT  
The majority of breast cancers are estrogen receptor positive (ER+). Blockade of estrogen 
biosynthesis by aromatase inhibitors (AIs) is the first-line endocrine therapy for post-
menopausal women with ER+ breast cancers. However, AI resistance remains a major 
challenge. We have demonstrated previously that increased GDNF/RET signaling in ER+ 
breast cancers promotes AI resistance. Here we investigated the efficacy of different small 
molecule RET kinase inhibitors, sunitinib, cabozantinib, NVP-BBT594 and NVP-AST487, 
and the potential of combining a RET inhibitor with the AI letrozole in ER+ breast cancers. 
The most effective inhibitor identified, NVP-AST487, suppressed GDNF-stimulated RET 
downstream signaling and 3D tumor spheroid growth. Ovariectomized mice were 
inoculated with ER+ aromatase-overexpressing MCF7-AROM1 cells and treated with 
letrozole, NVP-AST487 or the two drugs in combination. Surprisingly, the three treatment 
regimens showed similar efficacy in impairing MCF7-AROM1 tumor growth in vivo. 
However in vitro, NVP-AST487 was superior to letrozole in inhibiting the GDNF-induced 
motility and tumor spheroid growth of MCF7-AROM1 cells and required in combination 
with letrozole to inhibit GDNF-induced motility in BT474-AROM3 aromatase expressing 
cells. These data indicate that inhibiting RET is as effective as the current therapeutic 
regimen of AI therapy but that a combination treatment may delay cancer cell 
dissemination and metastasis.  
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Introduction  
 
Endocrine therapies have shown to be effective in patients that express estrogen receptor-
α (ERα, called hereafter ER). However, a significant portion of patients display de novo 
resistance or will develop resistance after an initial response. In postmenopausal patients, 
aromatase inhibitors (AIs), which block the conversion of androgens to estrogens, are the 
first-line treatment choice [1]. We, along with others, have demonstrated previously that a 
major cause of AI resistance is growth factor receptor activation that, via the 
PI3K/AKT/mTOR or MAPK pathways, drives ligand-independent ER activation [2-6]. 
These findings have been exploited clinically by combining AIs with mTOR [7, 8] or 
PI3K/AKT (NCT01437566) [9, 10] inhibitiors.   
 We have reported that activation of the REarranged during Transfection (RET) 
receptor tyrosine kinase by its ligand GDNF decreases response of ER+ breast cancer 
cells to endocrine therapy, including AIs, and that the transcriptional signature of RET 
downstream signaling has both prognostic and predictive value in breast cancer [4, 11-13]. 
Accordingly, the combination of the AI letrozole with the RET inhibitor NVP-BBT594 is 
more effective at suppressing GDNF-induced proliferation of RET+ ER+ breast cancer 
cells than either monotherapy [12, 14]. 
 In the current study, we first examined in vitro a number of small molecule inhibitors 
known to target RET that could be used in combination with an AI in vivo. We then chose 
the most effective inhibitor to assess its efficacy when combined with letrozole in an in vivo 
AI-sensitive breast cancer xenograft model.  
 
Results  
Impact of different small kinase inhibitors on GDNF-induced RET signaling in 
ER+/RET+ MCF7 cells 
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We have demonstrated that GDNF-dependent RET signaling promotes phosphorylation of 
ER and that, in these cells, ER transcriptional activity is blocked by siRNA-mediated 
downregulation of RET expression [4]. Further, the inhibitor NVP-BBT594 has been shown 
to impair RET signaling within nanomolar concentrations in vitro, however this compound 
showed toxicity in vivo [12]. Consequently, we first compared the efficacy of NVP-BBT594 
with other small molecule RET inhibitors [11]. Three day E2-deprived wild-type MCF7 cells 
were treated with the kinase inhibitors sunitinib (Figure 1A), cabozantinib (XL-184) 
(Figure 1B) and NVP-BBT594 (Figure 1C) at increasing concentrations and stimulated 
with 20 ng/ml GDNF in presence or absence of E2. Since RET has been shown to be an 
ER-dependent gene [14], the presence of E2 in the culture medium enhanced RET 
expression resulting in a stronger activation of GDNF-induced RET downstream signaling 
(Figure 1). Of the compounds used, NVP-BBT594 showed the highest suppression of 
GDNF-induced RET signaling, as assessed by RET, ERK1/2, AKT and ER 
phosphorylation. However, as stated above, NVP-BBT594 was unsuitable for extending 
these studies into in vivo models due to its in vivo toxicity. Consequently, we extended our 
studies to another RET inhibitor NVP-AST487, known to be well tolerated by mice [15, 16]. 
Western blot analysis revealed that NVP-AST487 and NVP-BBT594 have comparable 
RET inhibitory activity in wild-type MCF7 cells (Figure 2A). Importantly, similar results 
were obtained in MCF7 derivatives with stable expression of aromatase, MCF7-AROM1 
cells (Figure 2B), which provides a model of an AI sensitive breast cancer cells. In these 
experiments, MCF7-AROM1 cells were deprived of E2 for 3 days and then treated with 
androstenedione, which is converted into estrogen by the aromatase enzyme.  
 
NVP-AST487 reduces GDNF-induced MCF7-AROM1 cell growth in 3D in vitro assays  
Next we evaluated whether the inhibitory effects exerted by NVP-AST487 on MCF7-
AROM1 cells alter tumor cell growth in two independent physiologically relevant in vitro 
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assays. In the first, MCF7-AROM1 cells were subjected to a colony formation assay on a 
layer of thick Matrigel (Figure 3A,B) and in the second, cells were grown as three 
dimensional (3D) tumor spheroids in non-adherent conditions (Figure 3C-E). In both 
settings, MCF7-AROM1 cells were stimulated with androstenedione in the presence or 
absence of GDNF, NVP-AST487 and/or letrozole. When plated onto thick Matrigel, GDNF-
stimulated MCF7-AROM1 cells formed a significantly larger number of colonies than 
vehicle treated cells. Importantly, NVP-AST487 treatment was more effective than 
letrozole and blocking the GDNF-mediated increase in colony formation. Comparable 
results were obtained in the tumor spheroid formation assay (Figure 3C-E). Indeed, both 
the cell viability (Figure 3C) and the size of tumor spheres (Figure 3D) were significantly 
increased by GDNF treatment and this GDNF-mediated increase was fully blocked by 
NVP-AST487 treatment. In contrast, treatment with letrozole was only partially effective in 
impairing these GDNF-induced effects, suggesting that in a GDNF-enriched 
microenvironment (i.e. an environment enriched in GDNF secreting stromal cells [17, 18]) 
endocrine therapy alone may not be sufficient to impair RET-dependent tumor growth. We 
therefore evaluated if a combinatory therapeutic approach was of relevance in an in vivo 
setting. 
 
Combinatory treatment of NVP-AST487 and letrozole is not superior to 
monotherapies in reducing primary tumor growth 
MCF7-AROM1 cells were injected subcutaneously into immunocompromised mice where 
they formed tumors under androstenedione support, due to aromatase-mediated 
conversion into estrogen. Tumor-bearing mice were treated with AI letrozole, NVP-AST487 
or the combination and sacrificed after three weeks (Figure 4A). NVP-AST487, either 
when administered alone or in combination with letrozole, clearly impaired the RET 
signaling pathway as monitored by the reduction in RET protein levels and a decrease in 
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AKT phosphorylation (Figure 4B). Importantly, ERK phosphorylation was moderately 
suppressed by NVP-AST487, highlighting a discrepancy between the in vitro and the in 
vivo experimental settings, potentially due to other RET-independent ERK activating 
signaling pathways activated by the tumor microenvironment inputs. The decrease in RET 
protein levels induced by NVP-AST487 treatment was also confirmed at cellular level by 
immunohistochemistry, indicating that NVP-AST487 was able to access the RET+ cell 
compartment of the tumor (Figure 4C and Supplementary Figure S2). Moreover, NVP-
AST487 treatment alone impaired tumor growth. In these experiments it is important to 
note that there was no exogenous GDNF treatment indicating that in an in vivo setting 
RET signaling is active in these ER+ breast cancer xenografts. In contrast to results 
obtained in 3D in vitro assays, RET inhibition and letrozole treatment as monotherapies 
showed comparable effects in impairing xenograft growth and, moreover, the combination 
of NVP-AST487 and letrozole had no additional effect on tumor growth (Figure 4A).    
 These results are consistent with those obtained by Gattelli et al., using a RET+ 
syngeneic xenograft model of J110 mouse mammary tumor cells in FVB mice. J110 
tumor-bearing mice were treated with the NVP-AST487 inhibitor in the presence or 
absence of fulvestrant, an endocrine therapy that acts by targeting ER for degradation 
[16]. Again, the monotherapies had comparable effects in reducing primary tumor growth, 
but there was no enhanced effect when the two compounds were used in combination. 
Taken together these two studies, using distinct in vivo breast cancer models, indicate that 
RET signaling in tumor cells in vivo promotes tumor growth. Furthermore, inhibiting either 
RET signaling or ER signaling (either by blocking E2 production or promoting ER 
degradation) is comparable in reducing primary tumor growth. However, in the Gattelli 
study, RET inhibition combined with fulvestrant treatment led to a significant reduction in 
spontaneous metastasis, compared to either treatment alone [16].  
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NVP-AST487, but not letrozole, blocks GDNF-induced MCF7-AROM1 cell migration. 
Since MCF7-AROM1 cells do not spontaneously metastasize in mice, we could not directly 
assess the ability of NVP-AST487 to impair metastatic dissemination. Therefore, we 
investigated the effect of NVP-AST487 on MCF7-AROM1 cells motility in vitro, using the 
Boyden chambers assay. Treatment with GDNF resulted in a significant increase in MCF7-
AROM1 cell motility. Inhibition of aromatase activity with letrozole had no inhibitory effect 
on the migration of GDNF-treated cells, but this enhanced cell motility was fully reverted by 
NVP-AST487 treatment (Figure 5A). Importantly, in the time-frame of the cell migration 
experiments, neither monotherapies nor combination treatment impaired cell viability in 2D 
culture (Figure 5B) or increased cell apoptosis (Figure 5C), indicating that the reduction in 
cell motility observed in the presence of NVP-AST487 was due to direct inhibition of RET. 
These data were confirmed in an additional cell line, the ER+/HER2+ aromatase-
expressing BT474-AROM3 cells. These RET-positive cells express 1-log lower levels of 
the RET co-receptor GFRα1 when compared to MCF7 cells (not shown) and, importantly, 
GFRα1 levels are influenced by letrozole addition (Supplementary Figure S3). 
Consequently, soluble GFRα1 was added for optimal GDNF-induced RET signaling 
activation (Supplementary Figure S3) as previously described [12]. In Transwell 
migration assays, GDNF-induced RET activation resulted in a significant increase in 
BT474-AROM3 cell motility (Figure 5D), which was blocked to a similar extent by both 
letrozole and NVP-AST487 treatment. Importantly, combining the two compounds resulted 
in a greater inhibition of GDNF-induced BT474-AROM3 cell motility (One-way ANOVA, 
Bonferroni’s corrected, P<0.05; Figure 5D), without significantly impairing cell viability 
(Figure 5E) or promoting apoptosis (Figure 5F). 
  
Discussion  
In this study, we demonstrate that NVP-AST487 and NVP-BBT594 have comparable 
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potencies as inhibitors of GDNF-induced RET signaling in ER+ breast cancer cells in vitro. 
NVP-AST487 was chosen for in vivo validation as it has a superior safety profile in mice. 
Notably, we show that suppressing GDNF/RET signaling in vivo with NVP-AST487 is 
comparable in efficacy to AI treatment, the standard of care for postmenopausal ER+ 
breast cancer that is modeled in this experimental setting. 
 
Breast cancer cells can escape the inhibitory effects of endocrine therapies by increasing 
ER activity independently of estrogen [5]. We, along with others, have reported that the 
receptor tyrosine kinase RET plays an important role in endocrine therapies resistance in 
ER+ breast cancer cells by promoting ER phosphorylation, cell proliferation, and cell 
survival [4, 11, 12, 16]. Further, it has been recently demonstrated that RET expression 
and activation may also be physiologically relevant in triple negative (negative for ER, 
progesterone and HER2 receptor expression) [19] and HER2 positive breast cancers [19, 
20]. Interestingly, derivatives of the cytotoxic agent maytansine, a microtubule-interfering 
drug, conjugated to an anti-RET antibody show dose-dependent antitumor activity in RET 
expressing breast cancer xenograft models [20]. However, RET is expressed in the adult 
peripheral nervous system and treatment with this agent is also associated with on-target 
neuropathy. As a consequence, there remains a need for selective RET inhibitors that 
could be of potential clinical application in breast cancer but with reduced toxicity. 
Encouraging data has come from treating in vivo breast cancer patient-derived xenografts 
(PDXs) with the small kinase inhibitor vandetanib [19]. Although vandetanib reduced RET 
activation and promoted tumor regression in a subset of PDXs, it is important to note that 
this inhibitor also targets other tyrosine kinases, in particular VEGFR and EGFR, and that 
vandetanib induced an anti-angiogenic response in all PDX tumors independent of their 
RET or EGFR expression levels.  
 Since RET expression and activation is associated with endocrine therapy 
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resistance, there is a rationale for combining endocrine agents with RET inhibitors. 
Spanheimer and coworkers have recently reported that the selective ER antagonist 
tamoxifen and vandetanib had comparable efficacy in reducing MCF7 tumor growth in in 
vivo. Furthermore, combining the two compounds was significantly more effective in 
reducing tumor growth than either agent alone [21]. However, this result is discordant with 
that of Gattelli and coworkers who investigated the effects of combining a RET inhibitor 
with endocrine therapy in vivo using the J110 breast cancer murine model [16]. They 
reported in J110 xenografts, no additive effect of combining a RET inhibitor with either 
fulvestrant or tamoxifen [16], consistent with the findings reported here using an AI-
sensitive human xenograft model. Importantly, in the J110 model the authors reported a 
strong effect of the RET inhibition on reducing metastatic dissemination, particularly when 
combined with fulvestrant or tamoxifen, indicating that RET activation can both promote 
tumor growth and represent an important requirement for J110 tumor cell dissemination.  
 In the current study, we demonstrate that, as previously reported [22, 23], MCF7-
AROM1 xenografts are sensitive to the AI letrozole. In this experiment, it is notable that the 
concentration of letrozole used (i.e. 1 mg/kg/day) slowed tumor growth. However, the 
same concentration in alternative letrozole-sensitive ER+ xenograft model was sufficient to 
induce complete tumor remission [24]. These differences may be due to the different cell 
models used, different levels of aromatase expression and/or to a different androgen-
dependency that these models may display. 
 Since MCF7-AROM1 cells do not form metastases in mice, we could not directly 
assess the ability of NVP-AST487 to impair metastatic dissemination in when used in 
combination with an AI. However, it was striking that in in vitro cell migration assays, 
treatment with letrozole alone had no inhibitory effect on GDNF-induced MCF7-AROM1 
cell motility whereas NVP-AST487 treatment resulted in an effective impairment. 
Interestingly, in an alternative model, letrozole treatment reduced BT474-AROM3 cell 
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motility but full blockade was achieved only by combining the RET inhibitor and letrozole.  
 In summary, the data presented support the hypothesis that RET inhibitors , such as 
NVP-AST487, could both impair primary tumor growth and tumor dissemination, thereby 
providing a potential therapeutic advantage when used in combination with AIs in post-
menopausal ER+ breast cancers. 
 
Material and Methods  
Cell lines and assay 
All cell lines were STR (PCR/short tandem repeat) profiled by DNA Diagnostic Centre 
(DCC, London, UK). Wild-type MCF7 human breast cancer cells were maintained in 
phenol red-free RPMI 1640 supplemented with 10% fetal bovine serum (FBS, Euroclone), 
2 mM glutamine, and 1 nM 17-β estradiol (E2, Sigma). MCF7 cells expressing full-length 
human aromatase MCF7-AROM1 [22] were employed as a model of AI-sensitive cells, 
and maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, and 1 mg/mL 
Geniticin/G418 (Invitrogen). For estrogen deprivation, wild-type or AROM1 MCF7 and 
BT474-AROM3 cells were cultured for 3 days in phenol red-free RPMI-1640 medium plus 
10% dextran charcoal-treated (DCC) FBS and 2 mM glutamine (DCC medium). After 72 h, 
MCF7-AROM1 and BT474-AROM3 cells were treated with 10 nM of androstenedione 
(Sigma), which is converted into estrogens by aromatase, and after 24 h with the AI 
letrozole (Sigma). Cell viability, Western blot analysis, 3D colony forming and Annexin V/PI 
apoptosis assays were as previously reported [4, 12, 25]. 
 
Compounds 
NVP-AST487 (N-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-N'-[4-[[6-
(methylamino)-4-pyrimidinyl]oxy]phenyl]-urea) and NVP-BBT594 (5-[[6-(acetylamino)-4-
pyrimidinyl]oxy]-2,3-dihydro-N-[4-[(4-methyl-1-piperazinyl) methyl]-3-
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(trifluoromethyl)phenyl]-1H-indole-1-carboxamide) were provided by Novartis 
Pharmaceuticals, Basel (Switzerland). Cabozantinib and sunitinib were purchased from 
Tocris Bioscience. 
 
Tumor spheroids growth assay 
1 x 103 MCF7-AROM1 cells per well were seeded in 96-well ultra-low attachment plates in 
phenol red-free RPMI supplemented with 10% DCC FBS and 10 nM androstenedione [26]. 
After 24 hours, assembled spheroids were stimulated with 20 ng/ml GDNF (BD 
Biosciences) and treated with 100 nM NVP-AST487 and/or 100 nM letrozole. Medium was 
replaced every 3 days. Spheroid growth was monitored by collecting images of the 
spheroids and subsequent size quantification using ImageJ software. Cell viability 
measured at day 6 with CellTiter-Glo luminescent assay according to the manufacturer’s 
instructions (Promega, Madison, WI, USA) using a Victor 2V Multilabel HTS counter 
(Wallac-Perkin Elmer, Herts, UK).  
 
Colony Proliferation Assay 
Growth factor reduced and phenol red-free Matrigel (BD Biosciences, Oxford, UK) was 
diluted 1:1 in PBS and 0.2 mL per well was plated into 24-well tissue culture dishes and 
left at 37 °C for 2–3 h. Next, 1 x 104 cells were seeded per well and cultured overnight. The 
following day, cells were stimulated with GDNF (20 ng/mL) and treated with letrozole, 
NVP-AST487 or the combination as indicated. Medium was replaced every 3 days and 
colonies larger than 200 μm were counted at day 10. 
 
In vitro Transwell motility assay 
For motility assay, cells were serum starved overnight and seeded into the upper chamber 
of 8 µm-pore Transwells (Corning) in serum-free growth medium, with or without the 
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indicated compounds. Cells were allowed to migrate towards complete growth medium for 
48 hours. Non-moving cells were removed mechanically and the underside of the 
Transwells was stained with DiffQuick solution (BD Biosciences) as previously reported 
[27]. Chemotaxis was evaluated by counting the cells migrated to the lower surface of the 
filters (six randomly chosen fields). 
 
In vivo experiments 
MCF7-AROM1 xenografts were established as previously described [28]. In brief, 1 x 107 
MCF7-AROM1 cells were inoculated subcutaneously into ovariectomized female Ncr 
Foxhead nude 6- to 8- week-old mice (Harlan). Throughout the course of the experiment, 
mice were treated daily with androstenedione via intradermal injection (100 μg/day). 
Tumors were grown to ~8 mm diameter and then the mice were assigned to the following 
treatment groups. All treatments were given daily. Vehicle, 10% N-methyl-pyrollidone 
(NMP)/90% polyethylene glycol (PEG300); letrozole, 1 mg/kg in 150 μL of 10% NMP/90% 
PEG300; NVP-AST487, 50 mg/kg/d; combination, combination of letrozole and NVP-
AST487. Tumor growth was assessed by caliper measurements of the two largest tumor 
diameters. Volumes were calculated according to the formula: a×b2×π/6, where a and b 
are orthogonal tumor diameters. All animal work was carried out with UK Home Office 
approval.  
 
Immunostaining 
For RET immunohistochemistry (IHC), antigen retrieval was carried out by microwave 
irradiation for 5 minutes at full power (900 W) in citrate buffer pH 6.0. Anti- Ret (E1N8X) XP 
antibody (Cell Signaling technology) was optimized to give robust IHC staining of formalin-
fixed paraffin-embedded material and was applied at 1/100 dilution (see Supplementary 
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Figure 1). The stained slides were then scanned on a whole slide scanner (Nanozoomer 
2.0-HT, Hamamatsu, Japan).  
 
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism Software as reported in the 
figure legends and Results. 
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Figure legends 
Figure 1.  NVP-BBT594 impairs RET downstream signaling at nanomolar 
concentrations in a dose dependent manner. Wild-type MCF7 cells were grown in 
complete medium (E2+) or in E2-deprived DCC medium (E2-) for 3 days, serum-starved 
for the last 24 hours and pre-treated with the indicated concentrations of (A) sunitinib, (B) 
cabozantinib, or (C) NVP-BBT594 for 90 minutes before 30 minutes GDNF (20 ng/ml) 
stimulation. Total cell lysates were subjected to western blotting using the indicated 
antibodies. Tubulin was used as a loading control. Molecular size markers are in kDa. 
 
Figure 2.  NVP-BBT594 and NVP-AST487 have comparable inhibitory effects on RET 
downstream signaling in both wild-type and aromatase-expressing (AROM1) MCF7 
cells. (A) Wild-type MCF7 cells were serum-starved for 24 hours before pre-treating with 
NVP-AST487 or NVP-BBT594 for 90 minutes before GDNF (20 ng/ml) stimulation for 30 
minutes. For the experiments performed in the absence of E2, wild-type MCF7 cells were 
3 day E2 deprived in DCC medium before serum starvation. (B) MCF7-AROM1 cells were 
E2 deprived for 3 days in DCC medium and stimulated with androstenedione (10 mM) for 
the last 24 hours. The cells were then serum-starved for a further 24 hours and pre-treated 
with the indicated concentrations of NVP-AST487 or NVP-BBT594 for 90 minutes before 
GDNF (20 ng/ml) stimulation for 30 minutes. Total cell lysates were subjected to western 
blotting using the indicated antibodies. Tubulin was used as a loading control. Molecular 
size markers are in kDa. 
 
Figure 3.  NVP-AST487 reduces GDNF-induced MCF7-AROM1 cell growth in 3D in 
vitro assays. MCF7-AROM1 cells deprived of E2 for 3 days in DCC medium were 
stimulated with 10 nM androstenedione and then maintained with or without GDNF (20 
ng/ml) in the presence or absence of NVP-AST487 (100 nM) and/or letrozole (100 nM) as 
 21
indicated. Cells were subjected to (A,B) colony formation assays on Matrigel (10 days), (C) 
cell viability assay (6 days) or (D) spheroid formation assays performed in non-adherent 
conditions (6 days). Data represent mean ±SEM, n=3 independent experiments. (A) Two-
way ANOVA, Bonferroni corrected ***, P<0.001. (B) Representative pictures of the assay 
described in A. Scale bar, 1 mm. C and D, One-way ANOVA; Bonferroni corrected; **, 
P<0.01; ***, P<0.001. (E) Representative phase contrast images of spheres quantified in 
D. Scale bar:  400 µM. 
 
Figure 4.  Combination treatment of NVP-AST487 and letrozole is not superior to 
monotherapies in reducing primary tumor growth. Ovariectomized mice under 
androstenedione support were inoculated with MCF7-AROM1 cells. Following 
randomization, mice were treated daily with vehicle, letrozole, NVP-AST487 or letrozole 
plus NVP-AST487 as described in the Methods (n = 10 mice per group). (A) Tumor 
volumes show as fold change relative to day 1 of treatment ±SEM (2-way ANOVA, Tukey’s 
corrected; **, P<0.01, ***, P<0.001). At the end of the experiment, tumors were halved for 
(B) extraction of total lysates (n = 3 tumors per treatment group) for western blotting as 
indicated. GAPDH was used as a loading control. Molecular size markers are in kDa. 
Dotted line indicate two separate gels, run in parallel and exposed for equal lengths of time 
and (C) RET immunohistochemistry. Representative images are shown. Scale bar, 200 
μm. 
 
Figure 5. NVP-AST487, but not letrozole, reduces GDNF-induced MCF7-AROM1 cell 
motility. MCF7-AROM1 (A-C) and BT474-AROM3 (D-F) cells deprived of E2 for 3 days in 
DCC medium were stimulated with androstenedione (10 nM) in the presence or absence 
of letrozole (100 nM), GFRα1 (100 ng/ml), GDNF (20 ng/ml) and/or NVP-AST487 (100 
nM). (A,D) Cell motility in Transwells was measured after 48 hours. One-way ANOVA, 
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Bonferroni’s corrected, **, P<0.01, ***, P<0.001.  Representative images of DiffQuick 
strained Transwell filters are shown. 4X magnification. (B,E) Cell viability was measured 
after 48 hours. Data represent mean ±SEM, n=3 independent experiments. One-way 
ANOVA, Bonferroni’s corrected, ns: not significant. (C,F) Apoptosis was measured using 
the PI/AnnexinV assay. Bar graphs show mean percentage ±SEM of cells that are alive, 
undergoing early or late apoptosis and cells that are dead. One-way ANOVA revealed no 
significant differences between the groups.  
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Supplementary Figure 1 
Optimization of RET XP antibody for immunohistochemical staining of 
FFPE section of xenograft tumor 
 
MDA-MB-231 and HEK293 (RET negative) and RET overexpressing HEK293 
cells (RET positive) were cultured on tissue culture dishes, removed by 
scraping and pelleted. Cell pellets were fixed in 4% paraformaldehyde 
overnight and then subject to formalin fixation and paraffin embedding. 3 µm 
(micron) FFPE sections were cut and stained with the anti-RET XP antibody 
as described in Methods. Scale bar, 100 µm.  
MDA-MB-231 RET-HEK293 HEK293 
Supplementary Figure 2 
Representative whole IHC RET slides of MCF7-AROM1 xenografts. 
Ovariectomized mice under androstenedione support were inoculated with 
MCF7-AROM1 cells. Following randomization, mice were treated daily with 
vehicle, letrozole, NVP-AST487 or letrozole plus NVP-AST487 as described in 
the Methods (n = 10 mice per group). Representative whole tumor IHC RET 
slides of vehicle, letrozole, NVP-AST487 and letrozole plus NVP-AST487-
treated human MCF7-AROM1 xenografts. Scale bar, 1 mm.  
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Supplementary Figure 3 
BT474-AROM3 cells RET components and signaling characterization.  
A, Gene expression profiling of RET and GFRA1 in the BT474-AROM3 breast 
cancer cell line. B, Total  cell  protein  extracts  were  subject  to  western  
blotting.  NVP-AST487  blocks  GDNF-induced  RET  downstream  signaling.  
MCF7-2A  cells were E2-deprived for 3 days, serum-starved overnight and 
treated with 100 nM NVP-AST487 for 90 min followed by GDNF stimulation 
(20 ng/ml) and GFRα1 (100 ng/ml) for 30 min. Total cell protein extracts were 
subject to western blotting.  
A 
P-RETTyr905 
RET 
P-AKTSer473 
AKT 
P-ERSer167 
P-ERK1/2 
ERK1/2 
GFRα1+GDNF 
AST487 + 
+ + 
- 
- 
- 
B 
